819P - Implementation of targeted therapy in Denmark for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA...

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anticancer Agents
Renal Cell Cancer
Biological Therapy
Presenter Anne Soerensen
Authors A.V. Soerensen1, F. Donskov2, G.G. Hermann3, N.V. Jensen4, H. Spliid5, E. Bergan6, K. Fode2, P.F. Geertsen1
  • 1Department Of Oncology, University Hospital of Copenhagen Herlev, 2730 - Herlev/DK
  • 2Department Of Oncology, Aarhus University Hospital, Aarhus/DK
  • 3Department Of Urology, University Hospital of Copenhagen Rigshospitalet, Copenhagen/DK
  • 4Department Of Oncology, Odense University Hospital, Odense/DK
  • 5Section For Statistics, Informatics And Mathematical Modelling, Technical University of Denmark, Kongens Lyngby/DK
  • 6Denmark, Pfizer, Ballerup/DK



Treatment options for metastatic renal cell carcinoma (mRCC) have expanded since the introduction of targeted therapies. The impact of these new treatment options on overall survival in a complete national cohort of patients is unclear.


To analyze Overall Survival (OS), Progression Free Survival (PFS) and Time to Treatment Failure (TTF) in a complete national cohort of patients.

Design, setting and participants

All Danish patients with mRCC starting first line treatment with immunotherapy, TKIs or mTOR-inhibitors between 2006 and 2010 were included. Baseline and outcome data were collected retrospectively. Untreated patients referred for treatment were also assessed.

Outcome measurements and statistical analysis

OS, PFS and TTF was calculated using the Kaplan-Meier method. Differences between OS and treatment year were assessed using the log rank test. Differences in distributions were tested with the Chi-square test.

Results and limitations

Between 2006 and 2010, a total of 1073 patients were referred. Of these, 759 patients received first line treatment and 314 received no systemic treatment. The proportion of treated patients increased from 64% in 2006 to 75% in 2010 (p = 0.02). In 2006 22% received targeted therapy and this increased to 75% in 2010 (p < 0.00001). In 2006 21% of first line patients received second line treatment compared to 41% in 2010 (p = 0.01). From 2006 to 2010 we observed an improved median OS from 11.5 to 15.7 months (p = 0.03), improved median PFS from 4.1 to 5.5 months (p = 0.001) and an improved median TTF from 3.1 to 4.9 months (p = 0.006) for first line treatment. The untreated population of 314 patients had a median OS of 3.1 months from date of metastatic disease with no significant change from 2006 to 2010.


In a complete national cohort of patients, implementation of targeted therapy has resulted in improved treatment options and outcome for patients with mRCC.


A.V. Soerensen: has received a research grant/funding from Pfizer.

F. Donskov: has received a research grant from Novartis.

E.Q. Bergan: Employee of Pfizer Denmark Aps.

All other authors have declared no conflicts of interest.